Literature DB >> 2399912

Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity.

J S Cheigh1, H Kim, K H Stenzel, L Tapia, J F Sullivan, W Stubenbord, R R Riggio, A L Rubin.   

Abstract

We studied the clinical course of 59 lupus patients with end-stage renal disease (ESRD) to determine their long-term prognosis and delineate the evolution of their lupus activity. The study population was predominantly female (86%) and young (mean age, 27.4 years), and they were observed for a mean of 6.5 years from the inception of dialysis. At the time dialysis was initiated, only 21 patients (35.6%) had clinically active systemic lupus erythematosus (SLE). The remaining patients progressed to ESRD despite the absence of clinical lupus activity. Lupus activity was clinically apparent in 55.4% of patients in the first year, 6.5% in the fifth, and none in the tenth year. In 45% of patients, lupus activity was clinically inactive at entry to ESRD and remained inactive throughout the observation period. Serological activity declined proportionally, but to a lesser extent than clinical activity. Cumulative patient survival was 81.1% and 74.6% at the fifth and tenth year, respectively, from the inception of dialysis treatment; similarly it was 78% at the fifth and tenth year after the transplantation. Graft survival was 60.4% at the fifth and 45.5% at the tenth year. No one had recurrence of clinical lupus nephritis in the graft for up to 16 years of follow-up. Fourteen patients died from either infectious or cardiovascular complications, but none from SLE per se. This long-term study with a large number of lupus patients confirms our previous findings that the progression of renal disease to ESRD may be mediated by nonimmunologic mechanisms, as well as immunologic insults.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2399912     DOI: 10.1016/s0272-6386(12)81017-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  13 in total

1.  Lupus activation with cerebritis following pegylated interferon in a hemodialysis patient.

Authors:  Sanjay Kumar Agarwal; Charanjeet Lal; Sabahat Husain Zaidi
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

2.  New-onset systemic lupus erythematosus in a long-term hemodialysis patient with acute pleuritis and pneumonitis.

Authors:  Hiroto Hiyamuta; Shunsuke Yamada; Ryusuke Yotsueda; Shoko Hasegawa; Toshiaki Nakano; Masatomo Taniguchi; Hiroshi Tsukamoto; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  CEN Case Rep       Date:  2014-11-07

3.  Recurrence of lupus nephritis after kidney transplantation.

Authors:  Gabriel Contreras; Adela Mattiazzi; Giselle Guerra; Luis M Ortega; Elaine C Tozman; Hua Li; Leonardo Tamariz; Cristiane Carvalho; Warren Kupin; Marco Ladino; Baudouin LeClercq; Isabel Jaraba; Decio Carvalho; Efrain Carles; David Roth
Journal:  J Am Soc Nephrol       Date:  2010-05-20       Impact factor: 10.121

Review 4.  Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis.

Authors:  Mariadelina Simeoni; Ramona Nicotera; Maria Colao; Maria Lucia Citraro; Elena Pelagi; Annamaria Cerantonio; Nicola Comi; Giuseppe Coppolino; Giorgio Fuiano
Journal:  Int Urol Nephrol       Date:  2015-10-05       Impact factor: 2.370

Review 5.  Prognosis in systemic lupus erythematosus.

Authors:  J M Esdaile
Journal:  Springer Semin Immunopathol       Date:  1994

Review 6.  Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literature.

Authors:  Patrícia Mattos; Mittermayer B Santiago
Journal:  Clin Rheumatol       Date:  2012-03-14       Impact factor: 2.980

7.  Lupus nephritis in a pediatric renal transplant recipient.

Authors:  L Fox; P G Zager; A M Harford; K S Tung; S M Smith
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

Review 8.  Hematologic aspects of end-stage renal failure.

Authors:  P Zachée; J Vermylen; M A Boogaerts
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

9.  Early post-operative serum albumin level predicts survival after curative nephrectomy for kidney cancer: a retrospective study.

Authors:  Yongquan Tang; Zhihong Liu; Jiayu Liang; Ruochen Zhang; Kan Wu; Zijun Zou; Chuan Zhou; Fuxun Zhang; Yiping Lu
Journal:  BMC Urol       Date:  2018-12-06       Impact factor: 2.264

10.  Prescribing Patterns of Hydroxychloroquine and Glucocorticoids Among Lupus Patients After New-Onset End-Stage Renal Disease.

Authors:  Anna Broder; Wenzhu B Mowrey; Ana Valle; Mimi Kim; Candace H Feldman; Kazuki Yoshida; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-06-13       Impact factor: 5.178

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.